Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
Merck Sharp & Dohme LLC
Nicoletta Colombo; Emese Zsiros; Gabriella Parma; Eliana Rulli; Alexandra Sebastianelli; Mariusz Bidzinski; Carlos Gallardo; Emad Matanes; Kosei Hasegawa; Fatih Kose; Manuel Magallanes-Maciel; Rebecca A Herbertson; Sumitra Ananda; Judith R Kroep; Andreia Cristina de Melo; Philip R Debruyne; Jae-Weon Kim; Jalid Sehouli; Marc-Edy Pierre; Sakari Hietanen; Claudio Zamagni; Xin Lu; Bradley J Monk; Robert L Coleman; Xuan Peng; Karin Yamada; Agata M Bogusz; Thibault De La Motte Rouge; Xiaohua Wu; ENGOT-ov65/KEYNOTE-B96 investigators